IL-BAI
8.12.2022 19:43:43 CET | Business Wire | Press release
BAI, a nonprofit independent organization that delivers the most actionable insights in financial services, has named ten organizational winners and one honorable mention for the 2022 BAI Global Innovation Awards. Ten individuals were also named BAI Rising Stars. The awards are the industry’s leading program celebrating achievements in innovation, such as pursuing bold solutions for improving customer experience; implementing advanced technologies; and improving the lives of employees, customers, and communities.
Winners were selected by the BAI Innovation Circle, a panel of distinguished judges from around the world who are at the forefront of innovation in the financial services sector. Collectively, the winners represent outstanding contributions by teams and individuals and showcase inspiration from around the world. These global trailblazers have successfully designed and delivered innovations that positively improved customer relationships and served their communities in powerful ways.
“Innovation is a significant driver of the impact that successful financial services companies have on their customers and communities. The industry continues to bring powerful new approaches and solutions to better meet customer needs in new and different ways,” said Debbie Bianucci, president and CEO of BAI and Innovation Circle Judge. “The companies and individuals recognized this year were particularly creative and focused on addressing practical issues that made meaningful improvements for customers and employees.”
The 2022 BAI Global Innovation Award Winners and Honorable Mention are:
Banco Popular (Puerto Rico)
Innovation in Learning & Development
Innovation: Talent Lab & Skills Accelerator
Bank of America (USA)
Innovation in Digital Security
Innovation: Bank of America Security Center
Dreams Technology (United Kingdom)
Innovation in Digital Financial Planning
Innovation: Dreams ESG Innovation
Growsari (Philippines)
Innovation in Digital Commercial Financing
Innovation: GROWSARI.com, Powering the Digital Economy of the Philippines
Money Management International, Inc. (USA)
Innovation in Community Disaster Recovery
Innovation: Project Porchlight by MMI
MVB Bank (USA)
Innovation in Commercial Banking Onboarding Experience
Innovation: Onboarding Fintechs Better, Faster, Stronger…The Victor (ad)Vantage
Payten Teknoloji A.S.-Paratika (Turkey)
Innovation in Payments
Innovation: Paratika Crowdfunding e-Payment Project
Standard Bank (South Africa)
Innovation in Community Sustainability
Innovation: One Farm Share
TIAA (USA)
Innovation in Fraud Prevention
Innovation: TIAA Phone Authentication Risk Management (PARM)
Union Bank of India (India)
Innovation in HR Transformation
Innovation: Union Prerna
BMO (USA)
Innovation in Diversity, Equity & Inclusion (Honorable Mention)
Innovation: True Name
To further recognize innovation in financial services, a new award was established in 2022 to recognize individual leaders. The BAI Rising Star Award honors individuals who are up-and-coming leaders in financial services innovation. Leaders were nominated by their organizations and the recipients of the BAI Rising Star Award were selected based on their impact on and passion for innovation and their ability to drive positive change in their organizations.
The 2022 BAI Rising Star Award Winners are:
Sachin Chandna (United Arab Emirates), SVP, Head of Customer Intelligence & Engagement – Emirates NBD
Geoff Ellis (USA), Senior Director Application Development – Ally Financial
Ashley Fiore (USA), Chief Business Intelligence Officer – KlariVis
Snigdha Kumar (USA), Head of Product Operations – Digit
Larricia Lumpkins (USA), SVP, Senior Strategy Manager – Citizens Financial Group
Niki Neumann (South Africa), Executive, Lead Ecosystem Agriculture – Standard Bank Group
Dr. Chetna Pandey (India), Deputy General Manager – Union Bank of India
Stacy Regnier (USA), SVP, Retail Strategic Programs and Business Transformation – Commerce Bank
Bradwin Roper (South Africa), CEO – FNB Connect
Paul Whelpton (South Africa), Group Analytics Officer and Group Head of Trading – JUMO
For more information about the winners and their innovations, visit https://www.bai.org/globalinnovations/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221208005871/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom